• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Varian backs Oncora, launches Ethos radiotherapy device

Varian backs Oncora, launches Ethos radiotherapy device

September 16, 2019 By Sean Whooley

Varian Medical Systems updated logoVarian Medical (NYSE:VAR) said last week that it invested an unspecified amount in Oncora Medical and launched its Ethos artificial intelligence radiotherapy device.

Philadelphia-based Oncora makes software used to plan radiotherapy procedures. Palo Alto, Calif.-based Varian said the partnership with Oncora is aimed at accelerating its software development for radiation oncology.

“We envision a world where all patients have access to the highest quality cancer care regardless of their location,” oncology software solutions SVP Corey Zankowski said in prepared remarks. “Oncora Medical’s ability to aggregate vast amounts of patient data is designed to empower oncologists with a decision support tool to achieve the goal of elevating the standard of care across the country.”

“Oncora’s mission is to improve outcomes for cancer patients by developing intuitive software tools to better collect and learn from real world data,” added Oncora co-founder & CEO David Lindsay. “We look forward to partnering with Varian to develop and deploy innovative new tools in the fight against cancer.”

Varian yesterday revealed the launch of the Ethos AI-driven solution, which is designed adapt the therapy as tumor cell composition and location changes during treatment.

“Every patient deserves access to the best and most personalized cancer care,” oncology systems president Chris Toth said in prepared remarks. “Adaptive therapy is the future of personalized radiation therapy. Beginning with IMRT we were able to shape dose with more fidelity, and then image-guided radiation therapy allowed us to target with more precision. Ethos therapy, powered by AI, will allow us to adapt and personalize dose to every patient, every day in a typical treatment time slot. This is a transformational moment for cancer care.”

“Ethos therapy will enable our physicians to better visualize the changes in a patient’s anatomy and quickly adapt the therapy accordingly to help provide better treatments to patients,” added Dr. Poul Geertsen, of the Herley & Gentofte Hospital in Hellerup, Denmark. “We have already delivered the first Ethos therapy treatment and our clinical staff was impressed by the capabilities and the ability to deliver this advanced treatment in a typical timeslot.”

Shares of VAR were down -1.6% at $115.52 per share in late-morning trading today.

Filed Under: Imaging, Oncology, Radiosurgery/Radiation therapy, Software / IT Tagged With: Oncora, Varian Medical Systems

More recent news

  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy